Systemic and immunotoxicity of silver nanoparticles in an intravenous 28 days repeated dose toxicity study in rats
Source abstract
Abstract
Because of its antibacterial activity nanosilver is one of the most commonly used nanomaterials. It is increasingly used in a variety of both medical and consumer products resulting in an increase in human exposure. However, the knowledge on the systemic toxicity of nanosilver is relatively limited. To determine the potential systemic toxicity of silver nanoparticles (Ag-NP) with different sizes (20 nm and 100 nm) a 28-days repeated dose toxicity study was performed in rats using intravenous administration. The toxic effect of the 20 nm Ag-NP was performed using the bench mark dose (BMD) approach. Treatment with a maximum dose of 6 mg/kg body weight was well tolerated by the animals. However, both for 20 nm and 100 nm Ag-NP growth retardation was observed during the treatment. A severe increase in spleen size and weight was present which was due to an increased cell number. Both T and B cell populations showed an increase in absolute cell number, whereas the relative cell numbers remained constant. At histopathological evaluation brown and black pigment indicating Ag-NP accumulation was noted in spleen, liver, and lymph nodes. Ag-NP was also detected incidentally in other organs. Clinical chemistry indicated liver damage (increased alkaline phosphatase, alanine transaminase, and aspartate transaminase) that could not be confirmed by histopathology. Hematology showed a decrease in several red blood cell parameters. The most striking toxic effect was the almost complete suppression of the natural killer (NK) cell activity in the spleen at high doses. Other immune parameters affected were: decreased interferon-γ and interleukin (IL)-10 production by concanavalin-A stimulated spleen cells, increased IL-1β and decreased IL-6, IL-10 and TNF-α production by lipopolysaccharide stimulated spleen cells, increase in serum IgM and IgE, and increase in blood neutrophilic granulocytes. For the spleen weight a critical effect dose of 0.37 mg/kg body weight (b.w.) could be established. The lowest critical effect dose (CED) for a 5% change compared to control animals was observed for thymus weight (CED05 0.01 mg/kg b.w.) and for functional immune parameters, i.e. decrease in NK cell activity (CED05 0.06 mg/kg b.w.) and LPS stimulation of spleen cells (CED05 0.04 mg/kg b.w.). These results show that for nanosilver the most sensitive parameters for potential adverse responses were effects on the immune system.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoparticles: synthesis and applications · Immunotoxicology and immune responses
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (28)
Show source-provided references
1. Roszek · 2005
2. Nanosilver: a nanoproduct in medical application10.1016/j.toxlet.2007.10.004 ↗
3. Silver nanoparticles as a new generation of antimicrobials10.1016/j.biotechadv.2008.09.002 ↗
4. Nano-silver – a review of available data and knowledge gaps in human and environmental risk assessment10.1080/17435390902725914 ↗
5. Wijnhoven · 2009
6. Woodrow Wilson International Centre for Scholars · 2011
7. Use of nanosilver in consumer products10.2174/187221012798109318 ↗
8. Dekkers · 2007
9. Nano-silver e feasibility and challenges for human health risk assessment based on open literature10.3109/17435391003690549 ↗
10. Toxicological studies on silver nanoparticles: challenges and opportunities in assessment, monitoring and imaging10.2217/nnm.11.78 ↗
11. Pronk · 2009
12. Particle size dependent organ distribution of gold nanoparticles after intervenous administration10.1016/j.biomaterials.2007.12.037 ↗
13. The kinetics of the tissue distribution of silver nanoparticles of different sizes10.1016/j.biomaterials.2010.07.045 ↗
14. Blood clearance and tissue distribution of PEGylated and non-PEGylated gold nanorods after intravenous administration in rats10.2217/nnm.10.122 ↗
15. The effect of particle size on the cytotoxicity, inflammation, developmental toxicity and genotoxicity of silver nanoparticles10.1016/j.biomaterials.2011.08.085 ↗
16. Twenty eight day inhalation toxicity study of silver nanoparticles in Sprague-Dawley rats10.1080/08958370701432108 ↗
17. Subchronic inhalation toxicity of silver nanoparticles10.1093/toxsci/kfn246 ↗
18. Recovery from silver-nanoparticle-exposure-induced lung inflammation and lung function changes in Sprague Dawley rats10.3109/17435390.2011.648223 ↗
19. Twenty-eight day oral toxicity, genotoxicity, and gender related tissue distribution of silver nanoparticles in Sprague-Dawley rats10.1080/08958370701874663 ↗
20. Distribution, elimination, and toxicity of silver nanoparticles and silver ions in rats after 28-day oral exposure
21. Use of the bench mark dose approach in risk assessment
22. Developmental immunotoxicity of methylmercury: the relative sensitivity of developmental and immune parameters10.1093/toxsci/kfq223 ↗
23. Detection of immunotoxicity of benzo[a]pyrene in a subacute toxicity study after oral exposure in rats10.1093/toxsci/50.2.214 ↗
24. A probabilistic approach for deriving acceptable human intake limits and human health risks from toxicological studies: general framework10.1111/j.1539-6924.1998.tb01121.x ↗
25. Dose-response modeling of continuous endpoints10.1093/toxsci/66.2.298 ↗
26. Repeated dose toxicity and inflammatory responses in mice by oral administration of silver nanoparticles10.1016/j.etap.2010.05.004 ↗
27. Screening of xenobiotics for direct immunotoxicity in an animal study10.1016/j.ymeth.2006.09.003 ↗
28. Toxicity of silver nanoparticles – nanoparticle or silver ion?10.1016/j.toxlet.2011.11.002 ↗